Vanda Pharmaceuticals (VNDA) Set to Announce Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) will announce its earnings results after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.14. The company had revenue of $47.40 million during the quarter, compared to the consensus estimate of $47.28 million. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. Vanda Pharmaceuticals’s quarterly revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.03 EPS. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of Vanda Pharmaceuticals stock opened at $19.47 on Wednesday. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of 2,007.00 and a beta of 0.53. Vanda Pharmaceuticals has a one year low of $11.90 and a one year high of $23.50.

A number of equities analysts have commented on the stock. TheStreet upgraded shares of Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, October 26th. Oppenheimer set a $27.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 2nd. Cantor Fitzgerald restated a “hold” rating and set a $26.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 3rd. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Friday, October 12th. Finally, Seaport Global Securities restated a “buy” rating and set a $26.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, August 2nd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $26.86.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: Return on Investment (ROI) Defined, Explained

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply